Navigation Links
OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation

6. Empatic was associated with significant weight reduction through 48 weeks of treatment but also early discontinuations due to adverse events in approximately 37% of study participants. Zonisamide appeared to be the principal contributing factor, as a similar rate of discontinuations was evident among subjects receiving zonisamide IR therapy alone. Orexigen, in partnership with PharmaDirections, Inc. developed the proprietary SR formulation of zonisamide with the objective of improving its overall tolerability.

"We are excited that our novel, sustained release formulation of zonisamide was significantly better tolerated than the existing generic IR formulation. This is an important consideration in conditions such as obesity that often require longer-term maintenance therapy. Based on these results, we are eagerly awaiting the outcome of our ongoing 24 week Phase IIb multi-center study of Empatic, which incorporates our proprietary formulation of zonisamide SR," said Gary Tollefson, M.D., Ph.D., Orexigen's President and CEO.

About Orexigen(TM) Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, with an initial focus on obesity. Orexigen's lead combination product candidates targeted for obesity are Contrave(TM), which is in Phase III clinical trials, and Empatic(TM) (formerly Excalia(TM)), which is in a Phase IIb clinical trial. Both product candidates take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at




Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... (NYSE: DHR ) announced today that Henk ... and Amir Aghdaei and Henrik Roos have each been ... In his new role, Henk van Duijnhoven will ... Group and Sybron Dental Specialties.  Danaher,s Dental segment generated ...
... ALISO VIEJO, Calif., April 5, 2011 Avanir Pharmaceuticals, Inc. ... will present an overview of the company at the Future Leaders ... Location: Millennium Broadway Hotel & Conference Center, New York, ... Presentation time: 2:00pm ET A live ...
Cached Medicine Technology:Danaher Announces Executive Appointments 2
(Date:4/22/2014)... patients diagnosed with non-small cell lung cancer are 70 ... percentage, these elderly patients are not well represented in ... made it difficult to reach evidence based clinical recommendations. ... Task Force and Lung Cancer Group along with the ... opinion on managing treatment for elderly patients with non-small ...
(Date:4/22/2014)... trauma, illness, alcohol or other drug abuse, these stressors ... that can go awry and activate conditions such as ... , Until now, it has been unclear how much ... brain. Past studies have shown that when an expectant ... she experiences some trauma or illness, her baby may ...
(Date:4/22/2014)... intervention researchers have been informed that the National Institute ... Institutes of Health, will award an $8 million grant ... an experimental drug for stroke. , The drug, ... plasminogen activator, or rtPA the "clot-busting" drug currently ... laboratory rodent studies, 3K3A-APC, used in combination with rtPA, ...
(Date:4/22/2014)... a clinical trial led by Dana-Farber Cancer Institute ... approved a molecularly targeted drug as second-line treatment ... standard chemotherapy has failed. , The FDA approval ... manufacturer, Lilly Oncology, of Indianapolis. A monoclonal antibody ... sold under the name Cyramza, and is the ...
(Date:4/22/2014)... the University of Calgary,s Hotchkiss Brain Institute (HBI) uncovers ... as a means to restore connections after injury. Dr. ... molecule that directly regulates nerve cell growth in the ... prestigious journal Nature Communications , with lead authors ... made the surprising discovery that a protein called Retinoblastoma ...
Breaking Medicine News(10 mins):Health News:EORTC and SIOG update expert opinion on management of elderly patients with NSCLC 2Health News:Life stressors trigger neurological disorders, researchers find 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3Health News:FDA approves first targeted drug for advanced stomach cancer 2Health News:Scientists discover a new way to enhance nerve growth following injury 2
... , ... ... ... ...
... ... ... ... ...
... sheds light on brain mechanism related to processing images , ... recognizing faces may be relieved to know that the problem ... could be in their genes, new research suggests. , The ... genes) and 125 non-identical, same-sex twins (who share 50 percent ...
... C. Bray of the University of Calgary was recently ... for Sports Medicine,s (AOSSM) $250,000 Ligament and Tendon Repair ... Ligament and Tendon Healing: Role of Neuropeptides." ... of Calgary, and Per Renstrom and Paul Ackermann, both ...
... mechanisms of transport have important applicationstransport of nutrients ... aeration of agricultural soils, performance of chemical reactors, ... and the design of clay membranes for retaining ... has important roles in biology, physics, and chemistry, ...
... ... depression and stress with amazing technology; free assessments offered in March. , ... Arlington, TX (Vocus) February 24, 2010 -- The ... trigger anxiety, loneliness, depression and even thoughts of suicide. At New Life Brain Center™, ...
Cached Medicine News:Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 2Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 3Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 4Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 5Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 6Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 7Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 8Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 9Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 10Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 11Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 12Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 13Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 14Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 15Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 16Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 17Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 18Health News:Soyfoods Aid Those With Lactose Intolerance 2Health News:Soyfoods Aid Those With Lactose Intolerance 3Health News:Soyfoods Aid Those With Lactose Intolerance 4Health News:Soyfoods Aid Those With Lactose Intolerance 5Health News:Trouble Recognizing Faces Could Be Genetic 2Health News:$250,000 grant awarded for groundbreaking ligament and tendon repair research 2Health News:Where does the fluid go? 2Health News:Brain Balancing Gives Hope for Sufferers of Depression, Stress, and Insomnia at New Life Brain Center, 2Health News:Brain Balancing Gives Hope for Sufferers of Depression, Stress, and Insomnia at New Life Brain Center, 3
Complete Cataract Competence , OPMI VISU 140 is compact, good and economical. It's everything a cataract specialist needs today....
BD Vacutainer® Specialty Tubes - Acid Citrate Dextrose (ACD)...
... BD Vacutainer® SST™ Tubes ... a polymer gel for ... used for serum determinations ... provide an efficient means ...
MONOJECT Red/Yellow Mottled Stopper...
Medicine Products: